Foreign drug companies scrambling to build the TCM patent into domestic drug firms soft rib

        After novartis, a multinational drug giant glaxosmithkline has announced a try to use Chinese native medicine ingredient for drug development in China. In addition, the selection and local natural plant medicine research base "marriage" of multinational pharmaceutical companies are also more and more. Foreign drug companies appetite seems to be getting better and better, start targeting emerging field of traditional Chinese medicine (TCM).

        "New medical reform for traditional Chinese medicine development, and traditional Chinese medicine in China has a broad public basis, believe the future of local market demand will be more and more big." Professor at sun yat-sen university first hospital affiliated regions Zhang Shijun said. At the same time, experts fear, although holding secret recipe, resources, but domestic drug firms if not taking the path of standardization of traditional Chinese medicine (TCM), or will in the future ceded market share to foreign companies.

        Several multinational drug companies targeting the Chinese medicine market

        GSK China r&d centre President ZangJing five said, for Chinese medicine research and development will be integrated into some advanced technology, and will rely on the company's r&d center in China for the job. To this, analysis of the personage inside course of study thinks, the use of multinational pharmaceutical companies in China r&d center for research and development of traditional Chinese medicine is the practice of "ground", developers will be more familiar with Chinese traditional medicine of China. Before that, novartis, President of China's ministry of non-prescription drugs Jiang Huaceng announced that future novartis will specifically for Chinese market research and development of Chinese herbal medicine, and there will be sales in 500 million yuan of above conditions of m&a of domestic medicine companies.

        According to understand, as early as 2001, novartis has signed an agreement with Chinese academy of sciences, Shanghai institute of medicine, invested $2 million to develop Chinese medicine. At present, there have been several drug companies racing to go about traditional Chinese medicine (TCM) to carry out the modernization development, Shanghai institute of medicine alone and at the same time cooperate with MSD and well-known pharmaceutical companies such as Johnson & Johnson. According to introducing, Shanghai institute of medicine, is the nation's largest natural plant medicine research base, most of these foreign drug companies partner because of the traditional Chinese medicine and natural medicine project.

        Need to improve the level of scientific research ability and market operation

        In fact, foreign drug companies had ever tasted "sweetener" in the field of traditional Chinese medicine (TCM). Learned, novartis has worked with military academy of medical sciences, biotechnology research institute jointly developed a patent coartem Chinese medicine, then through the British GMP authentication, so that novartis anti-malarial drugs market ranks second in the world.

        "China faces very embarrassing situation, it is with thousands of years of tradition, may have an awkward." Guangdong armed police hospital ent said lombok constant, director of the center regions, TCM products currently on the market there is still a serious phenomenon of variable quality, and traditional Chinese medicine (TCM) preparations in exports accounted for very small actually, most of domestic traditional Chinese medicine (TCM) didn't apply for a patent, instead of being neighbors South Korea and Japan are taken a lot of, Chinese medicine patent by foreign registered amounted to more than 1000. "There are two big problems, it is the standardization of traditional Chinese medicine (TCM) problem; 2 it is the patent consciousness is not strong, business savvy enough."

        Is reported that the United States patent application for the "ginseng royal jelly", South Korea has applied for patent bezoar sedative bolus, folium ginkgo preparations of sell like hot cakes on the market such as Germany, Japan JiuXinDan is Chinese traditional medicine products. "Actually these products we all have the most orthodox formula, but is to further scientific research ability and the market operation level is not enough." Experts said.

        Have learned, at present the world plant medicine market annual sales of more than $16 billion, while exports of Chinese native medicine preparation in our country only around $100 million, accounts for only 5% of them. "Foreign drug companies can tap into unfamiliar areas of traditional Chinese medicine (TCM), is it know weakness in domestic Chinese medicine development at present, the main brand of science and technology, using their own strength to achieve modernization of traditional Chinese medicine (TCM), standardized production, and make composition mechanism and apply for patent." One industry source said, in fact, many domestic companies are holding secret recipe and master advantage resources, but if we don't "keep pace with The Times" analysis clear drug active and stable quality, uniform standard, the future is likely to be in the field of traditional Chinese medicine at home and abroad market, to relinquish their captured will share a lot of foreign companies.

(China national high and new technology industry leader)

The original links: http://field.10jqka.com.cn/20130225/c533005430.shtml